(1)
Real-World Outcomes, Treatment Patterns and T790M Testing Rates in Non-Small Cell Lung Cancer Patients Treated With First-Line First- or Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors from the Slovenian Cohort of the REFLECT: Outcomes and Treatments of EGFR-Mutated NSCLC Patients from Slovenia. Radiol Oncol 2022, 56 (3), 371-379.